Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Future Oncol
; 11(6): 965-73, 2015.
Article
en En
| MEDLINE
| ID: mdl-25760977
ABSTRACT
AIMS:
The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. PATIENTS &METHODS:
All patients received DOC 70 mg/m(2) every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses.RESULTS:
The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control.CONCLUSION:
Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
6_prostate_cancer
Asunto principal:
Taxoides
/
Neoplasias de la Próstata Resistentes a la Castración
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
Aspecto:
Patient_preference
Límite:
Humans
/
Male
Idioma:
En
Revista:
Future Oncol
Año:
2015
Tipo del documento:
Article
País de afiliación:
Italia